Cargando…
Is a single COVID-19 vaccine dose enough in convalescents ?
SARS-CoV-2 has infected more than 122 million persons worldwide. Most currently licensed COVID-19 vaccines require a two-dose course and many health systems are on a shortage of doses. The requirement for boosting the response after priming with the first dose is uncertain in convalescents already p...
Autores principales: | Focosi, Daniele, Baj, Andreina, Maggi, Fabrizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108188/ https://www.ncbi.nlm.nih.gov/pubmed/33950788 http://dx.doi.org/10.1080/21645515.2021.1917238 |
Ejemplares similares
-
Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021) -
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021) -
What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
por: Focosi, Daniele, et al.
Publicado: (2021) -
TTV viral load as a predictor of antibody response to SARS COV-2 vaccination
por: Focosi, Daniele, et al.
Publicado: (2023) -
Safety and immunogenicity of synchronous COVID19 and influenza vaccination
por: Baj, Andreina, et al.
Publicado: (2022)